355 related articles for article (PubMed ID: 10862569)
1. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
[TBL] [Abstract][Full Text] [Related]
2. A perspective on current and future uses of alternative models for carcinogenicity testing.
Goodman JI
Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
[TBL] [Abstract][Full Text] [Related]
3. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
4. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
5. Use of transgenic mice in carcinogenicity hazard assessment.
Jacobson-Kram D; Sistare FD; Jacobs AC
Toxicol Pathol; 2004; 32 Suppl 1():49-52. PubMed ID: 15209403
[TBL] [Abstract][Full Text] [Related]
6. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
7. Expectations for transgenic rodent cancer bioassay models.
Ashby J
Toxicol Pathol; 2001; 29 Suppl():177-82. PubMed ID: 11695555
[TBL] [Abstract][Full Text] [Related]
8. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
9. Carcinogenic chemical-response "fingerprint" for male F344 rats exposed to a series of 195 chemicals: implications for predicting carcinogens with transgenic models.
Johnson FM
Environ Mol Mutagen; 1999; 34(4):234-45. PubMed ID: 10618171
[TBL] [Abstract][Full Text] [Related]
10. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
Robinson DE; MacDonald JS
Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
[TBL] [Abstract][Full Text] [Related]
11. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
Battershill JM; Fielder RJ
Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
[TBL] [Abstract][Full Text] [Related]
12. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
[TBL] [Abstract][Full Text] [Related]
13. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
14. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice.
Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W
Toxicol Pathol; 1998; 26(4):501-11. PubMed ID: 9715509
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the uses of rats and mice for assessing carcinogenic risk from chemicals in humans.
Ward JM
Asian Pac J Cancer Prev; 2010; 11(1):18. PubMed ID: 20593921
[TBL] [Abstract][Full Text] [Related]
17. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
French J; Storer RD; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
[TBL] [Abstract][Full Text] [Related]
18. Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.
Recio L; Everitt J
Comp Med; 2001 Oct; 51(5):399-405. PubMed ID: 11924798
[TBL] [Abstract][Full Text] [Related]
19. Xpa and Xpa/p53+/- knockout mice: overview of available data.
van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
[TBL] [Abstract][Full Text] [Related]
20. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
